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Abstract
Adaptor proteins link surface receptors to intracellular signaling pathways, and potentially control 
the way cells respond to nutrient availability. Mice deficient in p66Shc, the most-recently evolved 
isoform of the Shc1 adaptor proteins and a mediator of receptor tyrosine kinase signaling display 
resistance to diabetes and obesity. Using quantitative mass spectrometry, we found that p66Shc 
inhibited glucose metabolism. Depletion of p66Shc enhanced glycolysis and increased the 
allocation of glucose-derived carbon into anabolic metabolism, characteristics of a metabolic shift 
called the Warburg effect. This change in metabolism was mediated by the mammalian target of 
rapamycin (mTOR), because inhibition of mTOR with rapamycin reversed the glycolytic 
phenotype caused by p66Shc deficiency. Thus, unlike the other isoforms of Shc1, p66Shc appears 
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to antagonize insulin and mTOR signaling, which limits glucose uptake and metabolism. Our 
results identify a critical inhibitory role for p66Shc in anabolic metabolism.
Introduction
A common mechanism through which activated receptor tyrosine kinases control 
intracellular pathways involves recruitment of SH2-containing proteins with regulatory or 
adaptor functions (1). For example, the Grb10 adaptor is an inhibitor of insulin signaling 
that is stabilized by mTOR-mediated phosphorylation and suppresses insulin sensitivity in 
vivo (2-5). Loss of inhibitors can result in dysregulation of growth factor signaling, 
promoting the re-wiring of metabolic pathways in a manner that supports rapid growth and 
cell survival. A major change that occurs in such proliferating cells is enhanced glucose 
uptake and catabolism, accompanied by increased lactate production, a phenomenon 
referred to as the “Warburg effect” (6, 7). This re-wiring provides proliferating cells with 
biosynthetic precursors from increased glucose-derived carbon intermediates that are 
essential for increasing cell biomass.
The gene for the Shc1 adaptor protein encodes three isoforms in mammals: p46, p52 and 
p66. These proteins share a modular arrangement of a phosphotyrosine binding (PTB) 
domain, a collagen homology 1 (CH1) region, and a Src homology 2 (SH2) domain (Fig. 
1A). p66Shc and p52Shc or p46Shc (p52/p46Shc) are encoded by two transcripts that differ 
in the use of alternative 5′ coding exons, whereas p46Shc and p52Shc originate from 
different translation start sites in the same mRNA, such that p46Shc is an N-terminally 
truncated form of p52Shc (8). p52/p46Shc isoforms are scaffolds that associate with 
activated receptor tyrosine kinases (RTKs), and amplify signaling to the Ras-Erk MAP 
kinase and phosphatidylinositol 3′-kinase (PI3K)-Akt pathways. The p66Shc isoform 
emerged with vertebrates, and is characterized by an N-terminal collagen homology 2 (CH2) 
extension (9). p66Shc has been reported to promote oxidative stress and pro-apoptotic 
signaling in HeLa cells and murine embryonic fibroblasts (MEFs) (9-11). Unlike p52/p46, 
the abundance of p66Shc is substantially decreased in ErbB2 overexpressing breast cancer 
cell lines suggesting that p66Shc may function as an antagonist of p52/p46Shc, possibly 
acting as a tumor suppressor (12). Inactivation of p66Shc in mice improves glucose 
tolerance and insulin sensitivity (13, 14), and confers resistance to hyperglycemia-induced 
endothelial dysfunction (15). However, under nutrient stress conditions, mice lacking 
p66Shc are short-lived (16). These studies suggest that p66Shc may suppress metabolism by 
dampening growth factor signaling.
Using targeted mass spectrometry-based metabolomics, we have analyzed the effects of 
p66Shc on metabolic pathways. Our data suggests silencing of p66Shc improves glucose 
uptake, and redirects glucose carbon towards anabolic metabolism and increased cell size. In 
addition, we show that the effects of p66Shc are mediated, in part, through mTOR 
complexes 1 and 2 (mTORC1 and mTORC2, respectively). Our work reveals a role for 
p66Shc as an inhibitor of growth factor signalling and cell metabolism.
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Results
Loss of p66Shc enhances glycolytic metabolism
To elucidate the involvement of p66Shc in cellular metabolism, we performed a targeted 
metabolomics analysis using liquid chromatography-tandem mass spectrometry (LC-
MS/MS) in multiple reaction monitoring (MRM) mode. We measured ∼250 metabolites in 
positive or negative mode runs (table S1), and validated metabolite spectral patterns using 
standards. To assess the role of p66Shc in cancer cell metabolism, we initially used HeLa 
cells that were stably transfected with either a short hairpin shRNA that specifically targets 
the isoform p66Shc or a control hairpin (Fig. 1B) (17). When we analyzed the profiles of 
metabolites extracted from the two cell types, we noted that loss of p66Shc resulted in 
increased abundance of intermediates of glucose metabolism (Fig. 1C and fig. S1). 
Specifically, p66Shc deficiency was accompanied by significant increases in glucose-6-
phosphate (G6P), and downstream glycolysis intermediates including fructose-6-
bisphosphate (F6P), fructose-1,6-bisphosphate (F1,6BP), phosphoenolpyruvate (PEP), and 
pyruvate (Figure 1D). p66Shc-deficient HeLa cells produced more lactate than control cells, 
consistent with the Warburg effect. The metabolic shift also redirects glucose-derived citrate 
from the tricarboxylic acid cycle (TCA cycle) into lipid synthesis to generate biomass (18). 
Consistent with this effect, p66Shc-deficient cells had higher citrate concentrations (Fig. 
1D). These data suggest that depletion of p66Shc is sufficient to enhance anabolic 
metabolism in HeLa cells.
Loss of p66Shc promotes glucose metabolism through the pentose phosphate and 
hexosamine biosynthesis pathways
In addition to the role of these molecules in glycolysis, G6P and F6P are precursors of the 
hexosamine biosynthesis and the pentose phosphate pathways, which are essential anabolic 
pathways in proliferating cells. The hexosamine biosynthesis pathway provides UDP-
GlcNAc as a substrate for O-GlcNAcylation of cytosolic proteins, and N- and O-
glycosylation of proteins produced in the secretory pathway. The pentose phosphate 
pathway provides ribose for nucleic acid synthesis and NADPH to maintain the reductive 
environment of the cell. In HeLa cells lacking p66Shc, we observed a ∼ 4-fold increase in 
N-acetylglucosamine-6-phosphate (GlcNAcP), and a ∼ 2-fold increase in UDP-GlcNAc 
abundance, the major products of the hexosamine biosynthesis pathway (Fig. 1E). A 2-3 
fold increase in UDP-GlcNAc enhances N-glycosylation of growth factor receptors, thereby 
promoting positive feedback to signaling (19, 20). Concentrations of ribose-5-phosphate 
(R5P) and xylulose-5-phosphate (X5P) were also increased, which may involve the 
oxidative pentose phosphate pathway that contributes to redox balance (Fig. 1F).
Restoring p66Shc expression in p66Shc-deficient MEFs inhibits glycolytic metabolism
To test whether p66Shc was necessary for enhanced glycolytic metabolism, immortalized 
p66Shc KO MEFs were stably infected with either GFP or 3xFLAG-p66Shc retroviral 
vectors (hereafter referred to as KO and p66+ MEFs, respectively) (Fig. 2A). Principal 
component analysis (PCA) was used to evaluate replicate consistency, and revealed a 
notable difference in the overall metabolic profiles of the p66Shc KO and p66+ cells (fig. 
S2). Consistent with the p66Shc-mediated effects in HeLa cells, F6P and G6P were among 
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the metabolites with the most significant changes, and the abundance of glycolytic 
intermediates was generally lower in p66+ MEFs compared to the KO cells (table 1). The 
abundance of glycolysis intermediates changed to a similar extent in MEFs as in HeLa cells; 
we observed ∼ 3 fold decrease in G6P concentrations, and a concomitant decrease in 
downstream three-carbon glycolytic metabolites including PEP and lactate in p66+ cells 
(Fig. 2B).
The lower concentration of citrate in p66+ cells was accompanied by a concomitant decrease 
in the amounts of the fatty acid synthesis precursors acetyl-CoA and malonyl-CoA (Fig. 
2C). Malonyl-CoA is a high energy and committed intermediate in fatty acid biosynthesis 
pathway, and is thus exclusively an anabolic metabolite. These results suggest that p66Shc 
inhibits de novo lipid biosynthesis. In addition, the abundance of intermediates in the 
hexosamine biosynthesis and pentose phosphate pathways was decreased in p66+ MEFs 
(Fig. 2, D and E). This profile confirms that p66Shc deficiency in non-transformed cells 
enhanced glycolytic flux at the expense of decreasing oxidative mitochondrial metabolism. 
Indeed, p66Shc deficient MEFs displayed lower oxygen consumption (Fig. 2F) but 
improved energy utilization (AMP/ATP) (Fig. 2G).
p66Shc expression inhibits amino acid biosynthesis and pyrimidine metabolism
The difference in glucose uptake between p66Shc-deficient and p66Shc-competent MEFs 
was ∼33% at most. However, the difference in the abundance of glycolytic metabolites 
ranged between 1.5- 3 fold. These results suggested a contribution from other nutrients such 
as amino acids that reversibly exchange with glycolytic intermediates. We detected higher 
amounts of non-essential amino acids, including alanine, serine and aspartate, in p66Shc-
deficient MEFs (Fig. 3A). To determine whether the effect of p66Shc signaling on the 
steady state abundance of non-essential amino acids reflects regulation of metabolic flux 
through de novo synthesis, we measured the relative flux with a pulse of stable-isotope 
labeled 15N-glutamine. Increased incorporation of labeled nitrogen into non-essential amino 
acids was detected in p66Shc KO MEFs (Fig. 3B). Increased flux of nitrogen from 
extracellular glutamine into non-essential amino acids in p66Shc KO MEFs is consistent 
with utilization catabolism of glutamine and reprograming that favors anabolism.
Pyrimidine derivatives (dCTP and UTP) were among the top 10 metabolites whose 
abundance was significantly decreased in p66+ MEFs (Table 1). Pyrimidine nucleotides are 
required as high energy donors for phospholipid and glycoconjugate biosynthesis. p66+ 
MEFs showed lower amounts of the pyrimidine synthesis intermediates orotate and 
dihydroorotate as compared to knockout MEFs (Fig. 3C). These results confirm that p66Shc 
inhibits anabolic metabolic pathways, and demonstrate a prominent role for p66Shc in 
reprogramming cell metabolism towards glucose catabolism and oxidative respiration.
p66Shc regulates redox homeostasis
By associating with cytochrome c, p66Shc promotes the generation of reactive oxygen 
species (ROS) (10, 21). Consistent with these findings, we observed a higher ratio of 
reduced to oxidized glutathione (GSH/GSSG) in p66Shc KO MEFs compared to p66+ MEFs 
(Fig. 3D). The ratio of NADH/NAD+ also reflects the redox state of the cell (22), and a ∼ 3-
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fold increase in NADH/NAD+ indicates a more reducing environment in p66Shc-deficient 
cells (Fig. 3E). NADH is produced in the second half of glycolysis during the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-catalyzed step, and this may 
contribute to the altered NADH/NAD+ ratio. The higher GSH/GSSG ratio in KO MEFs is 
consistent with the reported lower amounts of ROS in p66Shc KO MEFs (21). A previous 
report has shown that ROS contributes to insulin resistance and decreases glucose 
metabolism (23).
p66Shc is necessary and sufficient to alter glucose uptake and metabolism
To directly test whether p66Shc alters glucose uptake, we measured 3H-labeled 2-deoxy 
glucose (2DG) uptake at different time points. The rate of 2DG uptake in p66Shc-deficient 
HeLa cells and in p66Shc KO MEFs was greater than in p66Shc-expressing cells (Fig. 4, A 
and B). Consistent with the enhanced glucose consumption and higher glycolytic 
metabolism in p66Shc-deficient cells we observed increased concentrations of extracellular 
lactate in the media of HeLa cells and MEFs lacking p66Shc (Fig. 4, C and D). However, 
Western blots showed no apparent difference in the abundance of glucose transporter 1 
(GLUT1) between p66Shc-competent and p66Shc-deficient cells (fig. S3).
To monitor the effect of p66Shc on glucose catabolism, we examined the metabolites 
of 13C-labeled glucose in control and p66Shc-deficient HeLa cells. The metabolism of 
[1,2-13C2] glucose generates M0, M1 and M2 mass isotopomers corresponding to ion 
fragments that contain zero, one or two labeled carbons, respectively (table S2). Rapid 
transfer of cells from unlabeled medium to identical medium containing [1,2-13C2]-labeled 
glucose ensures that metabolism is minimally disturbed (24). Consistent with enhanced 
glycolytic metabolism in p66Shc-depleted cells, the amounts of the M2-labeled form of G6P 
and downstream intermediates including M2 F6P and M2 pyruvate were increased in 
p66Shc-depleted HeLa cells (Fig. 4, F and G). p66Shc silencing enhanced the amount of 
labeled glucose-derived citrate and acetyl-CoA nearly 2 fold, consistent with the redirection 
of glucose-derived carbons towards lipid biosynthesis. Conversely, re-expressing p66Shc in 
p66Shc KO MEFs inhibited the increase in the abundance of [1,2-13C2] labeled glycolytic 
metabolites and downstream anabolic intermediates, including acetyl-CoA and citrate, in 
p66Shc-deficient cells (Fig. 4H). Additionally, p66Shc inhibited the de novo synthesis of 
amino acids (fig. S4). Collectively, our data suggest that p66Shc is necessary and sufficient 
to reprogram glucose utilization into anabolic pathways.
Lack of p66Shc enhances glycolytic flux and anabolic metabolism
To study the dynamics of incorporation of isotope-labeled glucose into downstream anabolic 
metabolites, we performed kinetics flux profiling in p66Shc KO and p66+ MEFs using 
[1,2-13C2] labeled glucose by measuring the relative amounts of labeled glycolytic 
intermediates over 6 time points (0, 1, 2.5, 5, 10, 15 min). Consistent with the steady state 
data, we found that p66Shc inhibited labeled-glucose flux into glycolytic intermediates such 
as pyruvate in p66+ MEFs (Fig. 5A). In addition, the amounts of labeled citrate, R5P and 
UDP-GlcNAc were lower in cells expressing p66Shc (Fig. 5, B-D). UDP-GlcNAc is a high-
energy donor required for protein glycosylation and an example of an anabolic metabolite in 
which the GlcNAc portion is not catabolized back to glucose (20). Overall, these results 
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suggest that increased glycolytic flux in p66Shc-deficient cells accounts for the observed 
increase in metabolites at steady state, consistent with a role for p66Shc as an inhibitor of 
glucose catabolism.
p66Shc inhibits growth factor signaling to the metabolic sensor mTOR
Several aspects of the metabolic profile of p66Shc KO MEFs resemble that of cells with 
chronic mTOR activation; these include enhanced amounts of glycolytic and pentose 
phosphate pathway intermediates (G6P, F6P, and R5P) (25), increased amounts of de novo 
pyrimidine metabolites (26, 27), and increased lipid biosynthesis precursors (acetyl-CoA 
and malonyl-CoA) (25). To monitor mTOR signaling, we examined phosphorylation of 
Thr389 in the ribosomal protein S6 kinase (S6K1), a substrate of mTORC1, and Thr473 in 
Akt which is a direct target of mTORC2 (28). Following serum stimulation, p66Shc-
deficient HeLa cells displayed markedly increased phosphorylation of both mTORC1 and 
mTORC2 targets compared to control cells, despite having equal abundance of the p52Shc 
and p46Shc isoforms (Fig. 6A). Similar results were obtained with insulin stimulation (Fig. 
6B). Pre-treatment of cells with the mTOR inhibitor Torin1 (29) abolished the 
phosphorylation of mTOR targets in both cell types confirming the specificity of the signal 
(Fig. 6A and 6B). We also found that amino acid activation of the mTORC1 pathway was 
enhanced in p66Shc-deficient HeLa cells (fig. S5A). In p66+ MEFs, p66Shc inhibited the 
activation of mTOR targets following stimulation with IGF-1 and insulin, but not with EGF 
(Fig. 6C). This observation is consistent with previous reports showing that p66Shc has little 
effect on EGF signaling (9). The phosphorylation of mTORC1 and mTORC2 targets was 
decreased in p66+ MEFs following serum (Fig. 6D) and amino acid stimulation (Fig. S5B). 
In contrast to the inhibitory effects of p66Shc expression on mTOR signaling in KO MEFs, 
mTOR activation was sustained in KO MEFs stably overexpressing the p52Shc isoform 
(Fig. 6E). This confirms earlier reports that the p66Shc and p52Shc isoforms have opposing 
effects attributable to the unique N-terminal CH2 region of p66Shc (9, 30).
Loss of p66Shc causes an increase in cell size
mTOR functions as a central regulator of cell growth (31). The inhibitory effect of p66Shc 
on mTOR activation therefore predicted that p66Shc deficiency would lead to a larger cell 
size. Indeed, stable re-expression of p66Shc in p66Shc KO MEFs caused a decrease in cell 
size as measured by FACS forward scatter analysis (Fig. 6F). These findings were 
confirmed using coulter counter measurement (fig. S6A). Conversely, HeLa cells depleted 
of p66Shc displayed an increase in median cell size, consistent with redirection of glucose-
derived carbon towards biomass synthesis (fig. S6B). Together, these results suggest that 
p66Shc acts as a negative regulator of the nutrient-sensing mTOR signaling pathway leading 
to inhibition of cell growth and anabolic metabolism.
Effects of p66Shc on glycolytic metabolism are mediated through mTOR
To determine which mTOR complex contributes to the metabolic phenotype observed in 
p66Shc null cells, we treated p66Shc KO and p66+ MEFs with rapamycin for 16 h, a time 
frame that inhibits both mTORC1 and mTORC2 enzymes (Fig. 7A). In line with reports 
linking mTORC1 and mTORC2 to glycolytic metabolism (25, 32, 33), we found that 
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inhibition of both mTOR complexes partly reversed the metabolic phenotype of p66Shc KO 
MEFs, notably diminishing the increase in the hexosamine biosynthesis pathway (UDP-
GlcNAc) and the pentose phosphate pathway (R5P) (Fig. 7B). A similar trend was observed 
in de novo pyrimidine synthesis (Fig. 7C). Furthermore, inhibition of Akt, a kinase that is 
upstream of mTORC1 and downstream of mTORC2 (28), significantly decreased the 
amounts of glycolytic metabolites in p66Shc-deficient MEFs (fig. S7).
p66Shc alters gene expression
To understand how p66Shc signals to mTORC1 and mTORC2, we attempted to find unique 
p66Shc binding partners by mass spectrometry. However, all proteins that bound to p66Shc 
in our experiments have also been reported to bind to p52Shc following serum stimulation 
(table S4) (34). The steady-state condition of p66Shc KO and p66+ MEFs is likely to include 
differences in gene expression. To address this question, we performed RNA-seq analysis 
comparing the expression profile of p66Shc KO and p66+ MEFs. Our data shows significant 
differences in the expression of ∼ 400 genes but not for genes encoding glycolytic enzymes, 
including hexokinase and phosphofructokinase, or those encoding glucose transporters 
(table S3). This suggests that changes in steady-state abundance of p66Shc regulates 
metabolism largely through signaling and posttranslational modification.
Discussion
Our results provide evidence that p66Shc expression is associated with dampened signaling 
response to insulin stimulation and reduced glycolytic metabolism. Hyperglycemia has been 
previously shown to induce p66Shc expression (35). Our data suggests that p66Shc mediates 
feedback inhibition of growth signaling and glucose metabolism in cells (Fig. 7D). For 
metabolites that are intermediates in both catabolic and anabolic directions, the delivery 
of 13C-labeled glucose reveals competing delivery from cold sources including storage 
products, autophagy and uptake of other nutrients. For central metabolites such as pyruvate, 
citrate, R5P and UDP-GlcNAc, our flux analysis show faster 13C incorporation and an 
increase to a higher steady state in p66Shc-deficient cells, indicating a larger contribution 
from 13C-glucose than the non-radioactive sources in cells lacking p66Shc.
Furthermore, p66Shc deficiency in mice improves glucose tolerance and insulin sensitivity 
(13, 14). p66Shc silencing in both transformed and non-transformed immortalized cells 
improves glucose uptake, increases lactate production, and metabolite abundance for fatty 
acid biosynthesis, the hexosamine pathway, pentose phosphate pathway and amino acids 
contributing to increased cell size. This metabolic shift depends in part on the mTOR 
pathway, because rapamycin treatment reversed the glycolytic shift caused by p66Shc loss 
(Fig. 4D). These effects are particularly striking because the p52Shc isoform is identical to 
p66Shc in all but the N-terminal CH2 region, and has the opposing function of promoting 
the activation of the Ras-Erk and PI3K-Akt pathways. p66Shc acts as an inhibitor of 
mTORC1 and mTORC2 signaling, pathways that support protein synthesis associated with 
increased cell size. mTOR inhibition reduced anabolic metabolites partially restoring the 
p66Shc-competent phenotype, suggesting that mTOR-independent pathways also contribute 
to p66Shc-deficiency phenotype. p66Shc expression has been inversely correlated to 
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tumorigenesis (12), which is consist with our results in which p66Shc loss enhances mTOR 
signaling and anabolic metabolism. It is possible that p66Shc competes with p52Shc for 
binding partners in a dynamic manner that disrupts downstream signaling to mTOR. Time 
courses for receptor recruitment of signaling complexes may reveal the molecular basis for 
p66Shc action on signaling and anabolic metabolism.
RNA-seq analysis showed no differences in expression of genes encoding metabolic 
enzymes and glucose transporters between p66Shc-competent and p66Shc-deficient cells. 
Transcripts showing a chance in abundance were clustered in the category of secretory 
proteins, and additional studies are required to assess their contribution to the p66Shc 
phenotype. Rapid forms of regulation such as allostery and posttranslational modifications 
to metabolic enzymes and transporters may account for much of the observed p66Shc-
depdendent metabolic reprogramming. However, on a longer time scale, the stable cell lines 
used in our experiments have adapted to p66Shc expression or loss, and the attendant 
changes in signaling and metabolism flux may be reinforced by some of the changes in gene 
expression.
In summary, our results indicate that the Shc1 locus not only regulates mitogenic signaling, 
but also modifies anabolic metabolism in an mTOR-dependent manner. Our data points to 
the prospect that monitoring or modulating p66Shc abundance could be important in the 
management of pathological conditions in which metabolic signaling is dysregulated, such 
as cancer and diabetes.
Materials and Methods
Reagents were obtained from the following sources: antibodies to phospho-Thr389 S6K1, 
phosho-Thr308 Akt, phospho-Ser473 Akt, Akt, and S6K1 from Cell Signaling Technology; 
mouse and rabbit Shc1 antibodies from BD transduction laboratories; FLAG and tubulin 
antibodies, amino acids, insulin, IGF-1, and EGF from Sigma-Aldrich; FuGENE 6, 
Complete Protease Cocktail from Roche; rapamycin from LC laboratories, DMEM from 
Gibco; Inactivated Fetal Calf Serum (IFS) from Hyclone, amino acid-free RPMI from US 
Biological; BCA assay reagent, protein G-sepharose from Pierce; Akt Inhibitor IV 
(EMD4Biosciences).
Cell lines and tissue culture
HeLa and MEFs were cultured in DMEM with 10% IFS and penicillin/streptomycin. 
p66Shc KO MEFs were kindly provided by P.G. Pelicci (IFOM). 3xFLAG-p66Shc 
expressing MEFs were generated by retroviral infection of gateway-compatible pMX vector 
with murine p66Shc cDNA. Stably infected cells were maintained under 1 μg/ml puromycin 
selection. For stable p66Shc knockdown in HeLa cells, we used the following hairpin 
sequence:
sense 5′-cgg aat gag tct ctg tca tcg ct (tt)-3′ and anti-sense 5′-ag cga tga cag aga ctc att ccg 
(tt)-3′
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Amino acid stimulation
Almost confluent cultures in 6-well culture plates were rinsed with amino acid-free RPMI 
once, incubated in amino acid-free RPMI for 50 minutes, and stimulated with 52 μg/ml 
leucine for 10 minutes. For amino acid starvation, cells in 10 cm culture dishes or coated 
glass cover slips were rinsed with and incubated in amino acid-free RPMI for 50 minutes, 
and stimulated with a 10× amino acid mixture for 10 minutes as indicated in the figures. 
Following stimulation, the final concentration of amino acids in the media was the same as 
in RPMI. The 10× amino acid mixture was prepared from individual amino acid powders.
Cell lysis and Western blots
Cells were rinsed once with ice-cold PBS and lysed in ice-cold lysis buffer (40 mM HEPES 
[pH 7.4], 2 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, and 0.5% NP-40, 
and one tablet of EDTA-free protease inhibitors (Roche) per 10 ml). The soluble fractions of 
cell lysates were isolated by centrifugation at 13,000 rpm for 10 minutes by centrifugation in 
a microfuge. Proteins were denatured by the addition of 2× sample buffer and boiling for 5 
minutes, resolved by 8% SDS-PAGE, and analyzed by immunoblotting for the indicated 
proteins in the figures.
Metabolomic profiling
The relative abundance of metabolites were determined in HeLa cells and MEFs using the 
following protocol (36): Cells were seeded in 6-well plate in replicates. After 24 h, the 
media were removed and the cells were washed 2-times with warm PBS, then the cells were 
placed on dry ice. The metabolites were immediately extracted by adding 1 mLof extraction 
solution (40% acetonitrile, 40% methanol, and 20% water) containing internal standards 
(500μg/ml and 300μg/ml of D7-Glucose and 13C915N-Tyrosine, respectively) and then the 
cells were scraped and collected in 1.5 mL vials. The mixture was shaken for 1 hr at 4°C and 
1400 rpm in a Thermomixer (Eppendorf, Germany). The samples were spun down at 14000 
rpm, for 10 min at 4°C (Eppendorf, Germany), and supernatants were transferred into fresh 
tubes to be evaporated to dryness in a CentreVap concentrator at 40°C (Labconco, MO). The 
dry extract samples were stored at -80°C until LC/MS analysis. The dry metabolite extracts 
were reconstituted in 100μL of water. For positive and negative mode analysis, sample was 
injected twice through reversed phase column an Inertsil ODS-3, 4.6 mm internal diameter, 
150 mm length, and 3 μM particle size (Dionex Corporation, CA).). In positive mode 
analysis, where the mobile phase gradient ramps from 5% to 90% of acetonitrile in 16 min, 
after 1 min at 90%, the composition returns to 5% acetonitrile in 0.1% acetic acid in two 
min. In negative mode, where the acetonitrile composition ramped from 5 to 90% in 10 min, 
after 1 min at 90%, the gradient returns to 5% acetonitrile in buffer-A (0.1% tributylamine, 
0.03% acetic acid, 15% methanol). The total runtime in both modes was 20 min, the samples 
were stored at 4°C, and the injection volume was 10 μL. An automated washing procedure 
was developed before and after each sample to avoid any sample carryover.
The eluted metabolites were analyzed at the optimum polarity in MRM mode on 
electrospray ionization (ESI) triple-quadrupole mass spectrometer (ABSciex4000Qtrap, 
Toronto, ON, Canada). The mass spectrometric data acquisition time for each run is 20 min, 
and the dwell time for each MRM channel is 10 ms. Common mass spectrometric 
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parameters are the same as tuning conditions described above, except: GS1 and GS2 were 
50 psi; CUR was 20 psi, and CAD was 3 and 7 for positive and negative modes, 
respectively, and source temperature (TEM) was 400°C. Signal was normalized to internal 
standard and cell number. Metaboanalyst was used to analyze the data (37). The LC-MS/MS 
system does not resolve hexose and hexoseamine isomers including glucose/galactose and 
GlcNAc/GalNAc. To monitor trends in metabolic pathways, we referred to these isomers in 
their glucose (Glc) forms.
Statistics
Unpaired two-tailed Student's t-tests were performed comparing two groups. For multiple 
comparisons analysis, we used one-way ANOVA followed by Bonferroni's post hoc test. All 
experiments represent at least three biological replicates.
[3H]-2-deoxy-d-glucose uptake assay
MEF and HeLa cells grown in 6-well plates were rinsed with HEPES-buffered saline [140 
mM NaCl, 20 mM HEPES, 5 mM KCl, 2.5 mM MgSO4, 1 mM CaCl2 (pH 7.4)]. 2-DG 
uptake was performed for 3, 5, and 10 min in HEPES-buffered saline containing 2 mM 
unlabeled 2-DG and 0.2 μCi/ml 2-[3H] DG at room temperature. The reaction was 
terminated by washing three times in ice-cold 0.9% NaCl (w/v). To quantify the 
radioactivity incorporated, cells were lysed with 0.05 N NaOH and lysates were counted 
with scintillation fluid in a β-counter. Nonspecific uptake was determined in the presence of 
cytochalasin B (10 μM) during the assay. The results are expressed as pmole 2-DG 
transported per min/mg of protein.
Oxygen consumption rate measurement
Cells were seeded at 50,000 cells/well in XF-24 cell culture plates. The day after the 
seeding, cell culture media was replaced with unbuffered RPMI and oxygen consumption 
was measured using an XF-24 Flux Analyzer as described in (38).
Isotope labeling and kinetic profiling
Media of cell cultures in 6-well dishes were replaced with unlabeled fresh DMEM 2h before 
exposure to labeled glucose. The media was then replaced with DMEM containing 25 mM 
[1,2-13C2]-labeled glucose or 15N-labeled glutamine for the times indicated in the figures 
legends (Cambridge Isotope Laboratories). Metabolites were extracted and analyzed as 
mentioned in the Metabolomics profiling section using different MRM transitions that were 
developed for 1,2 13C-glucose as detailed in table S1.
Mass spectrometry analysis of the p66Shc protein-interactions
The p66Shc protein interaction network was determined following a protocol described in 
(34). p66+ MEFs were washed three times with ice-cold PBS and lysed in NP40 lysis buffer 
(50 mM HEPES-NaOH, pH 8, 150 mM NaCl, 1 mM EGTA, 0.5% NP40, 100 mM NaF, 2.5 
mM MgCl2, 10mM Na4P2O7, 1 mM DTT, 10% glycerol) supplemented with protease and 
phosphatase inhibitors (50 mM β-glycerolphosphate, 10μgml–1 aprotinin, 10μgml–1 
leupeptin, 1 mM Na3VO4, 100 nM calyculin A, 1 mM PMSF (phenylmethylsulphonyl 
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fluoride)). The total cell lysates were centrifuged at 10,000 rpm for 15 min to pellet nuclei 
and insoluble material. Nuclear-free lysates were pre-cleared by one-hour incubation with 
protein A sepharose and normalized for total protein concentration using the Bio-Rad 
protein assay. 3x-FLAG-p66Shc was immunoprecipitated by incubating lysates with 5 μl 
(bed volume) anti-Flag M2 antibody-conjugated agarose for 4 h at 4 °C.
RNA-seq
cDNA library preparation using Illumina TruSeq RNA Sample Prep Kit v2 
(Cat#RS-122-2001). Briefly, 1 μg of high quality total RNA were isolated from p66Shc KO 
and p66+ MEFs to generate the cDNA library according to the Illunima's protocol. The 
generated barcoded cDNA library has an average fragment size of 350-400 bp. This bar-
coded library is quality checked with Agilent Bioanalyzer and quantified with qPCR using 
KAPA SYBR FAST Universal 2× qPCR Master Mix (Kapa Biosystem, Cat#KK4602). The 
quality checked libraries are then loaded on a flowcell for cluster generation using Illumina 
c-Bot and TruSeq PE Cluster Kit v3 (Cat#: PE-401-3001). Sequencing was done on 
HiSeq2000 with TruSeq SBS Kit v3 (pair-ended 200 cycles, Cat#: FC401-3001). The real-
time base call (.bcl) files are converted to fastq files using CASAVA 1.8.2 (on CentOS 6.0 
data storage and computation linux servers).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors dedicate the manuscript in memory of Dr. Tony Pawson who passed away during the revision process. 
The research was supported by grants from Genome Canada through the OGI, and funding from Ontario Research 
Fund Global Leadership Round in Genomics & Life Sciences (ORF-GL2) and Canadian Cancer Society to TP and 
JWD. JWD is also supported by grants from CIHR (MOP-62975), Sydney C. Cooper Program, and the Canada 
Research Chairs Program. The authors are indebted to P.G. Pelicci and G. Cortopassi for providing p66Shc null and 
control MEFs and K. Chan and C.Y. Ho for performing the RNA-seq experiments. We thank M. Stacey and K. 
Riabowol for critical reading of the manuscript, as well as J. Gish and J. Woodgett for their encouragement and 
insight.
Funding: D.M.S is supported by grants from the NIH, Department of Defense, and awards from the Keck and 
LAM Foundation. D.W.L is supported by Ruth Kirschstein National Research Service and NIH K99 Awards. 
D.M.S. is an investigator of Howard Hughes Medical Institute. M.A.S is supported by a Vanier Canada and Ontario 
Graduate Studentships.
References
1. Scott JD, Pawson T. Cell signaling in space and time: where proteins come together and when 
they're apart. Science. 2009; 326:1220–1224. [PubMed: 19965465] 
2. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe 
MB, Marto JA, Sabatini DM. The mTOR-regulated phosphoproteome reveals a mechanism of 
mTORC1-mediated inhibition of growth factor signaling. Science. 2011; 332:1317–1322. [PubMed: 
21659604] 
3. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villen J, Kubica N, Hoffman GR, Cantley LC, 
Gygi SP, Blenis J. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that 
negatively regulates insulin signaling. Science. 2011; 332:1322–1326. [PubMed: 21659605] 
Soliman et al. Page 11
Sci Signal. Author manuscript; available in PMC 2014 December 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
4. Wang L, Balas B, Christ-Roberts CY, Kim RY, Ramos FJ, Kikani CK, Li C, Deng C, Reyna S, 
Musi N, Dong LQ, DeFronzo RA, Liu F. Peripheral disruption of the Grb10 gene enhances insulin 
signaling and sensitivity in vivo. Mol Cell Biol. 2007; 27:6497–6505. [PubMed: 17620412] 
5. Smith FM, Holt LJ, Garfield AS, Charalambous M, Koumanov F, Perry M, Bazzani R, Sheardown 
SA, Hegarty BD, Lyons RJ, Cooney GJ, Daly RJ, Ward A. Mice with a disruption of the imprinted 
Grb10 gene exhibit altered body composition, glucose homeostasis, and insulin signaling during 
postnatal life. Mol Cell Biol. 2007; 27:5871–5886. [PubMed: 17562854] 
6. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic 
requirements of cell proliferation. Science. 2009; 324:1029–1033. [PubMed: 19460998] 
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646–674. 
[PubMed: 21376230] 
8. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Pawson T, Pelicci 
PG. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal 
transduction. Cell. 1992; 70:93–104. [PubMed: 1623525] 
9. Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G, Pawson T, Di Fiore PP, 
Lanfrancone L, Pelicci PG. Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on 
the EGF receptor-MAP kinase-fos signalling pathway. EMBO J. 1997; 16:706–716. [PubMed: 
9049300] 
10. Pinton P, Rimessi A, Marchi S, Orsini F, Migliaccio E, Giorgio M, Contursi C, Minucci S, 
Mantovani F, Wieckowski MR, Del SG, Pelicci PG, Rizzuto R. Protein kinase C beta and prolyl 
isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science. 2007; 
315:659–663. [PubMed: 17272725] 
11. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancone L, Pelicci PG. 
The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature. 
1999; 402:309–313. [PubMed: 10580504] 
12. Stevenson LE, Frackelton AR Jr. Constitutively tyrosine phosphorylated p52 Shc in breast cancer 
cells: correlation with ErbB2 and p66 Shc expression. Breast Cancer Res Treat. 1998; 49:119–128. 
[PubMed: 9696394] 
13. Ranieri SC, Fusco S, Panieri E, Labate V, Mele M, Tesori V, Ferrara AM, Maulucci G, De SM, 
Martorana GE, Galeotti T, Pani G. Mammalian life-span determinant p66shcA mediates obesity-
induced insulin resistance. Proc Natl Acad Sci U S A. 2010; 107:13420–13425. [PubMed: 
20624962] 
14. Tomilov AA, Ramsey JJ, Hagopian K, Giorgio M, Kim KM, Lam A, Migliaccio E, Lloyd KC, 
Berniakovich I, Prolla TA, Pelicci P, Cortopassi GA. The Shc locus regulates insulin signaling and 
adiposity in mammals. Aging Cell. 2011; 10:55–65. [PubMed: 21040401] 
15. Camici GG, Schiavoni M, Francia P, Bachschmid M, Martin-Padura I, Hersberger M, Tanner FC, 
Pelicci P, Volpe M, Anversa P, Luscher TF, Cosentino F. Genetic deletion of p66(Shc) adaptor 
protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl 
Acad Sci U S A. 2007; 104:5217–5222. [PubMed: 17360381] 
16. Giorgio M, Berry A, Berniakovich I, Poletaeva I, Trinei M, Stendardo M, Hagopian K, Ramsey JJ, 
Cortopassi G, Migliaccio E, Notzli S, Amrein I, Lipp HP, Cirulli F, Pelicci PG. The p66Shc 
knocked out mice are short lived under natural condition. Aging Cell. 2012; 11:162–168. 
[PubMed: 22081964] 
17. Kisielow M, Kleiner S, Nagasawa M, Faisal A, Nagamine Y. Isoform-specific knockdown and 
expression of adaptor protein ShcA using small interfering RNA. Biochem J. 2002; 363:1–5. 
[PubMed: 11903040] 
18. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson 
DA, Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 
2005; 8:311–321. [PubMed: 16226706] 
19. Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, Dennis JW. 
Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and 
differentiation. Cell. 2007; 129:123–134. [PubMed: 17418791] 
Soliman et al. Page 12
Sci Signal. Author manuscript; available in PMC 2014 December 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
20. Wellen KE, Lu C, Mancuso A, Lemons JM, Ryczko M, Dennis JW, Rabinowitz JD, Coller HA, 
Thompson CB. The hexosamine biosynthetic pathway couples growth factor-induced glutamine 
uptake to glucose metabolism. Genes Dev. 2010; 24:2784–2799. [PubMed: 21106670] 
21. Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, Pelliccia G, Luzi L, 
Minucci S, Marcaccio M, Pinton P, Rizzuto R, Bernardi P, Paolucci F, Pelicci PG. Electron 
transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger 
mitochondrial apoptosis. Cell. 2005; 122:221–233. [PubMed: 16051147] 
22. Fisher-Wellman KH, Neufer PD. Linking mitochondrial bioenergetics to insulin resistance via 
redox biology. Trends Endocrinol Metab. 2012; 23:142–153. [PubMed: 22305519] 
23. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of 
insulin resistance. Nature. 2006; 440:944–948. [PubMed: 16612386] 
24. Munger J, Bennett BD, Parikh A, Feng XJ, McArdle J, Rabitz HA, Shenk T, Rabinowitz JD. 
Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral 
therapy. Nat Biotechnol. 2008; 26:1179–1186. [PubMed: 18820684] 
25. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski 
R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning 
BD. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol 
Cell. 2010; 39:171–183. [PubMed: 20670887] 
26. Ben-Sahra I, Howell JJ, Asara JM, Manning BD. Stimulation of de Novo Pyrimidine Synthesis by 
Growth Signaling Through mTOR and S6K1. Science. 2013; 339:1323–1328. [PubMed: 
23429703] 
27. Robitaille AM, Christen S, Shimobayashi M, Cornu M, Fava LL, Moes S, Prescianotto-Baschong 
C, Sauer U, Jenoe P, Hall MN. Quantitative Phosphoproteomics Reveal mTORC1 Activates de 
Novo Pyrimidine Synthesis. Science. 2013; 339:1320–1323. [PubMed: 23429704] 
28. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and 
ageing. Nat Rev Mol Cell Biol. 2011; 12:21–35. [PubMed: 21157483] 
29. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, 
Gray NS. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-
resistant functions of mTORC1. J Biol Chem. 2009; 284:8023–8032. [PubMed: 19150980] 
30. Xi G, Shen X, Clemmons DR. p66shc negatively regulates insulin-like growth factor I signal 
transduction via inhibition of p52shc binding to Src homology 2 domain-containing protein 
tyrosine phosphatase substrate-1 leading to impaired growth factor receptor-bound protein-2 
membrane recruitment. Mol Endocrinol. 2008; 22:2162–2175. [PubMed: 18606861] 
31. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006; 
124:471–484. [PubMed: 16469695] 
32. Hagiwara A, Cornu M, Cybulski N, Polak P, Betz C, Trapani F, Terracciano L, Heim MH, Ruegg 
MA, Hall MN. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, 
and SREBP1c. Cell Metab. 2012; 15:725–738. [PubMed: 22521878] 
33. Lamming DW, Demirkan G, Boylan JM, Mihaylova MM, Peng T, Ferreira J, Neretti N, Salomon 
A, Sabatini DM, Gruppuso PA. Hepatic signaling by the mechanistic target of rapamycin complex 
2 (mTORC2). FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology. 2014; 28:300–315. published online EpubJan. 10.1096/fj.13-237743 
[PubMed: 24072782] 
34. Zheng Y, Zhang C, Croucher DR, Soliman MA, St-Denis N, Pasculescu A, Taylor L, Tate SA, 
Hardy WR, Colwill K, Dai AY, Bagshaw R, Dennis JW, Gingras AC, Daly RJ, Pawson T. 
Temporal regulation of EGF signalling networks by the scaffold protein Shc1. Nature. 2013; 
499:166–171. published online EpubJul 11. 10.1038/nature12308 [PubMed: 23846654] 
35. Xi G, Shen X, Radhakrishnan Y, Maile L, Clemmons D. Hyperglycemia-Induced p66shc Inhibits 
Insulin-Like Growth Factor I-Dependent Cell Survival via Impairment of Src Kinase-Mediated 
Phosphoinositide-3 Kinase/AKT Activation in Vascular Smooth Muscle Cells. Endocrinology. 
2010
36. Abdel Rahman AM, Ryczko J, Pawling J, Dennis JW. Probing the hexosamine biosynthetic 
pathway in human tumor cells by multitargeted tandem mass spectrometry. ACS chemical 
Soliman et al. Page 13
Sci Signal. Author manuscript; available in PMC 2014 December 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
biology. 2013; 8:2053–2062. published online EpubSep 20. 10.1021/cb4004173 [PubMed: 
23875632] 
37. Xia J, Wishart DS. Web-based inference of biological patterns, functions and pathways from 
metabolomic data using MetaboAnalyst. Nat Protoc. 2011; 6:743–760. [PubMed: 21637195] 
38. Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, Hutchins AW, Gultekin Y, 
Peterson TR, Carette JE, Brummelkamp TR, Clish CB, Sabatini DM. MCT1-mediated transport of 
a toxic molecule is an effective strategy for targeting glycolytic tumors. Nature genetics. 2013; 
45:104–108. published online EpubJan. doi:110.1038/ng.2471. [PubMed: 23202129] 
Soliman et al. Page 14
Sci Signal. Author manuscript; available in PMC 2014 December 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1. p66Shc deficiency enhances glycolytic metabolism and causes a Warburg shift
(A) Diagram of the three isoforms of mammalian Shc1. (B) Abundance of the three Shc1 
isoforms in HeLa cells stably expressing shRNAs targeting GFP or p66Shc. N = 3 biological 
replicates. (C) Summary of the changes in intracellular metabolite amounts associated with 
p66Shc knockdown in HeLa cells analyzed by LC-MS/MS. (D-F) Fold change of glycolytic 
(D), hexosamine biosynthesis pathway (E), and pentose phosphate pathway (F) 
intermediates in p66Shc-deficient and p66Shc-competent HeLa cells as measured by LC-
MS/MS. Glucose-6-phosphate (G6P); Fructose-1,6-phosphate (F1,6BP); 
Phosphoenolpyruvate (PEP), Fructose-6-phosphate (F6P); N-acetylglucosamine phosphate 
(GlcNAcP); Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), ribose-5-phosphate 
(R5P) and xylulose-5-phosphate (X5P). Error bars represent SD of three biological 
replicates (* p < 0.05, ** p < 0.01, *** p < 0.001).
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Fig. 2. Rescue of p66Shc expression in p66Shc KO MEF (p66+ cells) inhibits glycolytic 
metabolism in favour of oxidative metabolism
(A) Abundance of the three Shc1 isoforms in p66Shc KO MEFs stably infected with GFP 
(KO) or FLAG-p66Shc (p66+). N = 3 biological replicates. (B-E) p66Shc expression inhibits 
glycolytic metabolism. Data represents fold change of glycolytic intermediates (B), acetyl-
CoA (ACoA) and malonyl-CoA (MCoA) (C), pentose phosphate pathway intermediates (D), 
and hexosamine biosynthesis pathway intermediates (E) in p66Shc-deficient (white) and 
p66Shc-competent (black) MEFs as measured by LC-MS/MS. (G) p66Shc deficiency 
inhibits oxygen consumption rate as measured by XF-24 Flux Analyzer. (H) Relative 
amounts of AMP/ATP ratio in p66Shc KO and p66+ MEFs by LC-MS/MS. In all 
experiments, error bars represent SD of at least three biological replicates (* p < 0.05, ** p < 
0.01, *** p < 0.001).
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Fig. 3. p66Shc expression inhibits the biosynthesis of amino acids and pyrimidines and regulates 
redox homeostasis
(A) Fold change of steady state alanine, serine and aspartate, measured by LC-MS/MS. (B) 
Fold change of intracellular amounts of 15N-labeled alanine, serine and aspartate in p66Shc 
KO and p66+ cells grown in media containing 15N-glutamine for 2h. (C) Fold change of de 
novo pyrimidine synthesis intermediates, N-carbamoyl aspartate, orotate and UMP. (D and 
E) Relative amounts of the ratio of reduced/oxidized glutathione (GSH/GSSG) (D), and 
reduced/oxidized NAD+ (NADH/NAD+) (E) in p66Shc KO and p66+ MEFs. In all 
experiments, error bars represent SD of at least three biological replicates (* p < 0.05, *** p 
< 0.001).
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Fig. 4. p66Shc is necessary and sufficient to alter glucose uptake and glycolytic metabolism
(A and B) Tracing of 3H-labeled 2-deoxy glucose (2DG) uptake over time in p66Shc-
competent and p66Shc-deficient HeLa cells stably expressing shRNAs targeting GFP (A) or 
p66Shc and p66Shc KO and p66+ MEFs (B). (C and D) Fold change of extracellular lactate 
in media from p66Shc-competent and p66Shc-deficient HeLa (C) and MEFs (D). (E) 
Schematic diagram of 13C-labeling patterns of metabolic products with [1,2-13C2] labeled 
glucose as a tracer. Blue circles indicate 13C-labeled carbons. (F-G) Fold change of 13C-
labeled glycolytic (F), hexosamine biosynthesis pathway (G) intermediates in p66Shc-
competent (white) and p66Shc-deficient cells (black) HeLa cells. (H) 13C-labeled glycolytic 
intermediates in p66Shc KO (white) and p66+ (black) MEFs. Error bars represent SD of at 
least three independently prepared samples (* p < 0.05, ** p < 0.01, *** p < 0.001).
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Fig. 5. Glucose flux in p66Shc KO and p66+ MEFs
(A-D) Relative amounts of 13C-labeled pyruvate (A), citrate (B), and the pentose phosphate 
pathway intermediates E4P (C) and R5P (D) after incubating cells with [1,2-13C2] labeled 
glucose for the indicated time points. Data are represented as the ratio of 13C-labeled 
metabolites to an internal standard (D7-glucose). Error bars represent SD of at least three 
independently prepared samples with statistical significance p < 0.05.
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Fig. 6. p66Shc inhibits mTOR activation and cell size
(A) Effect of p66Shc on mTORC1-S6K1 and mTORC2-Akt activation. HeLa cells stably 
transfected with indicated shRNAs were serum starved, treated with either DMSO or Torin 
for 1 h, and then stimulated with serum (10 min). Cell lysates were analyzed for the 
indicated proteins and phosphorylation states by immunoblotting. N = 3 biological 
replicates. (B) Experiment was done as in (A) but cells were stimulated with 100 nM insulin 
(10 min). N = 3 biological replicates. (C) Effect of reconstitution of p66Shc expression in 
p66Shc KO MEFs on mTOR activation in response to EGF, insulin, and IGF1 stimulation. 
Serum-starved cells were stimulated with 100 nM EGF, IGF, or insulin (10 min). N = 3 
biological replicates. (D) Experiment was done as in (C) but cells were stimulated with 
serum. N = 3 biological replicates. (E) Stable expression of retroviral FLAG-p66Shc, but not 
FLAG-p52Shc, in p66Shc null cells inhibits the mTOR pathway. Experiment was done as in 
(C). N = 3 biological replicates. (F) Cell size distribution of KO and p66+ MEFs using flow 
cytometry forward scattering (right). Average cell size of KO and p66+ from three 
independent experiments is represented (left), *** p < 0.001.
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Fig. 7. mTOR mediates the effects of p66Shc on glycolytic and pyrimidine metabolism
(A) Rapamycin treatment for 16 h is sufficient to inhibit both mTORC1 and mTORC2 
signaling in p66Shc KO and p66+ MEFs. Cell lysates were analyzed for the indicated 
proteins and phosphorylation states by immunoblotting. N = 3 biological replicates. (B) 
p66Shc KO and p66+ MEFs were treated with vehicle or rapamycin for 16 h, and amounts 
of glycolysis, hexosamine biosynthesis, and pentose phosphate pathways metabolic 
intermediates were quantified by LC-MS/MS (ANOVA analysis, N = 3 biological 
replicates). (C) Fold change of UMP and CMP pyrimidine metabolites. Cells were treated as 
in (B). (D) Model for role of p66Shc in inhibiting growth factor signaling to glycolytic 
metabolism and biosynthetic pathways through inhibiting mTOR activation. Error bars 
represent SD of three independently prepared samples (* p < 0.05, ** p < 0.01, *** p < 
0.001).
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Table 1
The 10 metabolites that showed the most statistically significant changes of p66+ over KO MEFs. N = 3 
biological replicates. FDR: False discovery rate.
Metabolite Fold change p-value FDR
Dihydroxyacetone phosphate (DHAP) 0.23 2.44E-05 0.000244
Fructose 6-phosphate (F6P) 0.29 7.64E-05 0.000270333
Glucose 6-phosphate (G6P) 0.36 8.11E-05 0.000270333
Fructose 1,6-bisphosphate (F1,6BP) 0.29 0.000207 0.000452
Malonyl Co-enzyme A (MCoA) 0.30 0.000226 0.000452
Erythrose-4-phosphate (E4P) 0.26 0.000598 0.000915714
NADH/NAD+ 0.34 0.000641 0.000915714
Acetyl Co-enzyme A (ACoA) 0.29 0.001544 0.00193
2′-Deoxycytidine 5-triphosphate (dCTP) 0.41 0.00265 0.002944444
Uridine 5-triphosphate (UTP) 0.45 0.003853 0.003853
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